Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 27, 2018

Antiseizure properties of cannabidiol (CBD) are attenuated in the absence of transient receptor potential vanilloid 1 (TRPV1) receptors (S53.004)

Benjamin J. Whalley, Royston A. Gray, Colin G. Stott, Nicholas A. Jones
First published April 9, 2018,
Benjamin J. Whalley
1GW Research Ltd Cambridge United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Royston A. Gray
1GW Research Ltd Cambridge United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin G. Stott
1GW Research Ltd Cambridge United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas A. Jones
1GW Research Ltd Cambridge United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Antiseizure properties of cannabidiol (CBD) are attenuated in the absence of transient receptor potential vanilloid 1 (TRPV1) receptors (S53.004)
Benjamin J. Whalley, Royston A. Gray, Colin G. Stott, Nicholas A. Jones
Neurology Apr 2018, 90 (15 Supplement) S53.004;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Evaluate effect of CBD upon seizure threshold in wild-type (WT) and TRPV1 knockout (TRPV1−/−) mice.

Background: TRPV1 receptor expression is increased in rodent epilepsy models and temporal lobe epilepsy patients. CBD is a TRPV1 agonist that rapidly desensitizes TRPV1. A pharmaceutical formulation of purified CBD has been shown to reduce seizure frequency in Lennox-Gastaut and Dravet syndrome patients.

Design/Methods: Mice received intraperitoneal CBD (10–200 mg/kg; GW Pharmaceuticals), CBD vehicle (ethanol:kolliphorEL:saline, 1:1:18 ratio) 60 minutes before testing, the TRPV1 antagonist capsazepine (10 mg/kg in 2% DMSO), or diazepam (2.5 mg/kg in saline) 30 minutes before testing (n=12/group). A constant current stimulus (1–300 mA; 0.1 s duration) was delivered via corneal electrodes and mice assessed for tonic hind limb extension. Stimulus intensity was varied by a shock titration method and the current required to produce maximal seizures in 50% of animals tested (CC50) values calculated. Statistical analysis was performed using two-way ANOVA with post-hoc Sidak’s tests. Brain and plasma CBD concentrations were assessed by liquid chromatography/tandem mass spectrometry.

Results: There was a significant interaction between genotype and disease (F(6,154)=24.35; P<0.0001) and main effects of genotype (F(1,154)=169.6; P<0.0001) and treatment (F(6,154)=113.4; P<0.001) upon CC50 which arose from significantly attenuated responses in TRPV1−/− mice to CBD (50 & 100 mg/kg; each P<0.0001), diazepam (P<0.001) and capsazepine (P<0.05) when compared to WT. No significant difference in brain CBD concentrations was noted between WT and TRPV1−/− mice (P>0.05).

Conclusions: CBD dose-dependently increased seizure threshold in WT mice, an effect markedly reduced in TRPV1−/− mice. Brain CBD concentrations were consistent with those required for TRPV1 activation and desensitization, suggesting that CBD’s anticonvulsant effects in acute, generalized seizures are partially mediated via TRPV1 receptor interaction.

Study Supported by:

GW Research Ltd

Disclosure: Dr. Whalley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GW PHARMACEUTIALS (EMPLOYMENT). Dr. Whalley holds stock and/or stock options in GW PHARMACEUTICALS, which sponsored research in which Dr. Whalley was involved as an investigator. Dr. Gray has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GW Pharmaceuticals. Dr. Gray has received compensation for serving on the Board of Directors of GW Pharmaceuticals. Dr. Stott has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GW Pharmaceuticals. Dr. Stott has received compensation for serving on the Board of Directors of GW Pharmaceuticals. Dr. Stott holds stock and/or stock options in GW Pharmaceuticals, which sponsored research in which Dr. Stott was involved as an investigator. Dr. Jones has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GW Pharmaceuticals. Dr. Jones has received compensation for serving on the Board of Directors of GW Pharmaceuticals.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (9)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise